Observational studyCritical care (London, England)2023
Novel serum biomarkers for predicting neurological outcomes in postcardiac arrest patients treated with targeted temperature management.
Observational study in Critical care (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- 2025 Korean Guidelines for Cardiopulmonary Resuscitation: Part 6. Post-cardiac arrest care.Clinical and experimental emergency medicine · 2026Guideline
- European Resuscitation Council and European Society of Intensive Care Medicine guidelines 2025: post-resuscitation care.Intensive care medicine · 2025Guideline
- The role of serum biomarkers as prognostic indicators in pediatric cardiac arrest: a systematic review.Biomarkers in medicine · 2025Pooled it
- Grey matter volume reduction and its association with brain-enriched blood biomarkers in out-of-hospital cardiac arrest survivors.Scientific reports · 2025Trial
- Quantification of blood-based neurovascular unit biomarkers: an analytical platform comparison study.Resuscitation plus · 2026Article
- Brain neurovascular unit biomarkers: a hypothesis-driven paradigm to advance understanding of post-cardiac arrest cerebral injury.Annals of intensive care · 2026Review
- Prognostic Value of Serum S100B Protein for Neurological Outcomes After Cardiac Arrest: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2025Review
- Beyond blood-brain barrier disruption and molecular weight: compartmental kinetics of S100B and NSE for neurological prognostication after cardiac arrest.Critical care (London, England) · 2025Article
- Clinical use and reporting of neurofilament quantification in neurological disorders: A global overview.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Serum glial fibrillary acidic protein and protein gene product 9.5 for predicting neurological outcomes in cardiac arrest patients with cortical response to somatosensory evoked potentials.Resuscitation plus · 2025Article
- Application of multi-feature-based machine learning models to predict neurological outcomes of cardiac arrest.Resuscitation plus · 2024Review
- Electrical impedance tomography provides information of brain injury during total aortic arch replacement through its correlation with relative difference of neurological biomarkers.Scientific reports · 2024Article
- Higher levels of brain injury biomarker tau are associated with unfavorable outcomes in patients supported with ECMO following cardiac arrest.Resuscitation plus · 2024Article
- Plasma glial fibrillary acidic protein and tau: predictors of neurological outcome after cardiac arrest.Critical care (London, England) · 2024Observational
- Post Cardiac Arrest Care in the Cardiac Intensive Care Unit.Current cardiology reports · 2024Review
- Normal value of neuron-specific enolase for predicting good neurological outcomes in comatose out-of-hospital cardiac arrest survivors.PloS one · 2024Observational
- Predictive Performance of Neuron-Specific Enolase (NSE) for Survival after Resuscitation from Cardiac Arrest: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2023Review
- Confounding factors in article stating that Ubiquitin C terminal hydrolase predicts poor neurological outcome after cardiac arrest.Critical care (London, England) · 2023Article
- Developments in Post-Resuscitation Care for Out-of-Hospital Cardiac Arrests in Adults-A Narrative Review.Journal of clinical medicine · 2023Review
- Biomarkers in Cardiac Arrest: A Narrative Review.Therapeutic advances in pulmonary and critical care medicineReview
Corrections and comments
- Commented on by
Authors and funding
9 authors at 4 institutions in 3 countries.
Funding
Abstract
objectiveTo determine the clinical feasibility of novel serum biomarkers in out-of-hospital cardiac arrest (OHCA) patients treated with target temperature management (TTM).
methodsThis study was a prospective observational study conducted on OHCA patients who underwent TTM. We measured conventional biomarkers, neuron‑specific enolase and S100 calcium-binding protein (S-100B), as well as novel biomarkers, including tau protein, neurofilament light chain (NFL), glial fibrillary acidic protein (GFAP), and ubiquitin C-terminal hydrolase-L1 (UCH-L1), at 0, 24, 48, and 72 h after the return of spontaneous circulation identified by SIMOA immunoassay. The primary outcome was poor neurological outcome at 6 months after OHCA.
resultsA total of 100 patients were included in this study from August 2018 to May 2020. Among the included patients, 46 patients had good neurologic outcomes at 6 months after OHCA. All conventional and novel serum biomarkers had the ability to discriminate between the good and poor neurological outcome groups (p < 0.001). The area under the curves of the novel serum biomarkers were highest at 72 h after cardiac arrest (CA) (0.906 for Tau, 0.946 for NFL, 0.875 for GFAP, and 0.935 for UCH-L1). The NFL at 72 h after CA had the highest sensitivity (77.1%, 95% CI 59.9-89.6) in predicting poor neurological outcomes while maintaining 100% specificity.
conclusionNovel serum biomarkers reliably predicted poor neurological outcomes for patients with OHCA treated with TTM when life-sustaining therapy was not withdrawn. Cutoffs from two large existing studies (TTM and COMACARE substudy) were externally validated in our study. The predictive power of the novel biomarkers was the highest at 72 h after CA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.